Bluestar Genomics: David Mullarkey

Early cancer detection company Bluestar Genomics has appointed David Mullarkey as CEO. He will also join the company's board of directors. Current acting CEO and CSO Samuel Levy will continue in his role as CSO.

Mullarkey most recently served as president and CEO of DNA sequencing company Omniome, which was acquired by Pacific Biosciences in 2021. Prior to Omniome, Mullarkey served as president and chief operating officer of Ariosa Diagnostics, which was acquired by Roche in 2014. Mullarkey has also held leadership positions at Johnson & Johnson, Eli Lilly, Valeant Pharmaceuticals, and Dow Pharmaceutical Sciences.